More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.
Jonathan Lindner, MD, offers an update on the use of echocardiography and bubble contrast agents in a therapy role to help revascularize STEMI patients and increase drug and gene delivery.
CT findings that have historically been deemed as concerning relative to PE might not hold as much weight when it comes to associated risks as previously thought, new analysis suggests.
The new technique mixes MRI signals at different gradient pulse strengths and timings, offering better visualization of differences in the way water molecules move through tissues.
Artificial intelligence tools have proven to be beneficial in detecting pulmonary nodules on chest CTs of adults, but less is known about their utility in pediatric populations.
